A dozen three-letter acronyms have shown up in three years. HHC, THCP, CBDX, 10-OH-HHC, CBG9. None of them came out of nowhere. They are variations on a single starting molecule, produced by a small number of chemical reactions. Learn which reactions, and you can decode any new product on the shelf.
All of these acronyms describe the same architecture
A THC-type cannabinoid reads in two parts: a ring system, and a side chain of carbon atoms attached to that ring. The entire family is built by modifying one or the other.
Three terms are worth pinning down before going further. A phytocannabinoid occurs naturally in the plant, like CBD or CBG. A semi-synthetic compound starts from a hemp-derived molecule that has been chemically transformed in a lab. A metabolite is what the body produces while breaking down a parent molecule, and some are now manufactured directly rather than harvested. Product catalogs sort their inventory by acronym. Once the underlying chemistry makes sense, that shelf layout becomes readable.
Three chemical reactions explain almost the entire shelf
Hydrogenation. Hydrogen atoms are added to the THC ring, saturating it and removing a double bond. The product is hexahydrocannabinol, or HHC. That saturation makes the molecule more stable against oxidation and light than the THC it came from.
Hydroxylation. A hydroxyl group, one oxygen atom bonded to one hydrogen, is grafted onto position 10 of the ring. The result is 10-hydroxy-hexahydrocannabinol. Here is the part most product pages leave out: this molecule is not a recent invention. It appears in the scientific literature as far back as the 1980s, identified as a THC metabolite in animal studies. It is now produced directly in the lab, and it behaves as an agonist at both CB1 and CB2 receptors.
Side chain extension. In this case the ring stays put and only the tail of the molecule stretches. THC carries a five-carbon chain. THCP and CBDP carry seven. On paper it is the subtlest of the three modifications. In practice it is by far the most consequential.
Why side chain length changes potency
The relationship between chain length and biological activity has been documented for decades through structure-activity research. Three carbons is the minimum needed for the molecule to bind the CB1 receptor at all. Activity climbs from there, peaks somewhere around eight carbons, then falls off beyond that.
Cinzia Citti and colleagues measured the gap in 2019 in Scientific Reports, after isolating THCP from cannabis. CB1 affinity came in more than thirty times higher than THC, with an inhibition constant around 1.2 nanomolar against roughly 40 for THC. Lower number, tighter binding.
A 2025 review in iScience explains the physical mechanism. The CB1 binding site contains three hydrophobic cavities: a main pocket that holds the ring system, a long pocket formed by three of the receptor's helices and wide enough to accommodate a seven-carbon chain, and a sub-pocket angled toward the residues that trigger activation. A longer chain reaches that last zone. It does not merely fit inside the receptor, it presses the switch.
One caveat, from the same review. These numbers are contested. Published affinity values for THC alone range from 2.9 to over 40 nanomolar depending on the assay. Treat cross-molecule comparisons as orders of magnitude, not as physical constants.
Natural, semi-synthetic, synthetic: what the words mean
Natural means extracted from the plant without chemical modification: CBD, CBG, CBN, CBC. Semi-synthetic means a hemp molecule served as the starting point for a laboratory transformation. Synthetic means built entirely through chemistry, with no plant material involved.
CBDX belongs to the second category. It comes from the lab transformation of hemp-derived compounds, and its modified structure gives it mild activity at CB1 receptors, where CBD acts indirectly instead. Published pharmacological data on this molecule remains very thin, and no controlled clinical study has examined its long-term profile. The effect descriptions circulating online come from user reports, not from the literature.
Molecule or brand name?
Watch out for one common mix-up. CBX and CBDX are not the same thing. CBX, or cannabixanthone, is a rare plant cannabinoid with a tetracyclic biphenyl structure, and recent published work concludes that it interacts with neither CB1, nor CB2, nor TRPA1. It has nothing to do with the semi-synthetic CBDX sold in stores.
The same fog surrounds CBDP, CBG9, THCjd, HHC-P, and the growing list of proprietary house blends. Most of these are commercial labels rather than standardized molecules, and the formulation shifts from one manufacturer to the next. Two products carrying the same acronym from two different vendors can contain different things. Only the certificate of analysis tells you what is actually in the package you are holding.
What human research still cannot tell you
The contrast deserves to be stated plainly. European drug monitoring flagged nine new cannabinoids entering the market in 2023 alone, and the American picture has moved at a comparable pace since hemp was separated from marijuana under the 2018 Farm Bill. Against that, zero randomized controlled trials have been published on 10-OH-HHC or on CBDX. The striking numbers on THCP come from test-tube binding assays and animal models, not from human studies.
Put differently: the chemistry of these molecules is well described, their human pharmacology is not. Legal status is a separate matter and it varies, since federal treatment and state law do not always align on hemp-derived and synthetically derived compounds. Check the rules where you live before buying anything. Our position at Mana Botanics is simple: read the full molecule name on the certificate of analysis, never the acronym on the label.
